



S2 Fig. Progression-free survival according to ERCC1 levels (A) and treatment arms (B). Overall survival according to ERCC1 levels (C) and treatment arms (D). ERCC1, excision repair cross-complementation group 1; GP, gemcitabine and cisplatin; IP, irinotecan and cisplatin.